Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2022

In 2022, Fate Therapeutics, Inc.'s disclosed short interest ran from 12.23% of shares outstanding on 14 Jan 2022 to 22.98% on 30 Dec 2022, a change of +10.75 percentage points. The year's high was 22.98% on 30 Dec 2022 and its low 12.23% on 14 Jan 2022, averaging 19.53% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.54 days on 30 Nov 2022. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2022

2022 in figures

Start of year
12.23% (14 Jan 2022)
End of year
22.98% (30 Dec 2022)
Change
+10.75 pp
High
22.98% (30 Dec 2022)
Low
12.23% (14 Jan 2022)
Average
19.53%
Highest days to cover
22.54 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

Fate Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202212.23%8.49
31 Jan 202213.14%6.94
15 Feb 202214.41%13.10
28 Feb 202216.12%10.6010-K filed, results (8-K)
15 Mar 202216.43%12.60
31 Mar 202216.15%10.81
14 Apr 202216.75%16.02
29 Apr 202217.13%14.44
13 May 202218.52%8.5810-Q filed, results (8-K)
31 May 202221.19%13.96
15 Jun 202221.32%11.89
30 Jun 202222.77%11.17
15 Jul 202221.96%13.83
29 Jul 202221.75%20.45
15 Aug 202220.54%11.9510-Q filed, results (8-K)
31 Aug 202220.86%16.63
15 Sep 202221.44%14.80
30 Sep 202222.29%16.04
14 Oct 202222.45%19.87
31 Oct 202222.88%17.17
15 Nov 202222.77%13.1810-Q filed, results (8-K)
30 Nov 202221.84%22.54
15 Dec 202220.83%11.50
30 Dec 202222.98%5.64

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.